McKesson has delivered a powerful run over the past several years, and the share price sits near the top of its recent range. That kind of performance naturally raises a question for anyone looking at the stock today, which is whether the current valuation can be explained by the cash the business is expected to produce.
-
Over the past 5 years, McKesson has returned about 339.6%, which puts serious weight on whether that share price climb is still in step with its underlying cash flows.
-
The group's core role in pharmaceutical distribution and healthcare services can support relatively steady cash generation, which makes a closer look at how those cash flows stack up against the current price especially important.
-
Prefer to judge McKesson on earnings? See what McKesson's 24.4x P/E says about the price .
The stock's next move may depend on whether today's price near US$960.56 is well supported by the cash flows implied by a Discounted Cash Flow (DCF) view.
If you are considering whether McKesson's cash flows still justify this kind of share price increase, it can help to compare that question across 26 high quality undervalued stocks .
Does McKesson Look Undervalued on Cash Flow?
The Discounted Cash Flow (DCF) approach values McKesson by projecting the cash it could return to shareholders and then discounting that stream back to today. In this model, the business is treated as a mature but still growing cash generator, with latest twelve month free cash flow of about $6.0b and analyst forecasts that keep future cash flows in the multi billion dollar range.
Those projections feed into a 2 Stage Free Cash Flow to Equity setup, where the early years use analyst estimates and later years assume slower, more measured growth in dollar free cash generation. When that stream is discounted and compared with the current share price of $960.56, the DCF output suggests McKesson's estimated intrinsic value is substantially above the current share price, which points to a market price that lags the modelled cash flows. Find out what McKesson could be worth using our Discounted Cash Flow (DCF) estimate .
The McKesson Narrative: What Would Justify Today's Price?
Narratives pick up where the DCF puzzle for McKesson leaves off. They map out which paths for revenue growth, profitability and earnings power would need to play out for the stock to trade meaningfully higher or lower than today. Each scenario on Simply Wall St's Community page turns a single valuation output into a set of clear assumptions so you can see the future it rests on and watch how the real numbers compare over time.
One of the top community narratives on McKesson: roughly fairly valued
"Expansion of technology driven access platforms such as RxTS and CoverMyMeds, including programs for GLP 1 therapies and broader affordability and access solutions…"
Discover why this Narrative puts McKesson at roughly fairly valued .
The price of McKesson is only part of the story
Cash flows and valuation models explain what you pay, but the people setting priorities, allocating capital and deciding their own rewards can heavily shape what you actually get over time. See who runs McKesson and how they are paid .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include MCK .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
